Mankind Pharma Aims to Be Debt-Free by FY28, Targets Obesity and Consumer Health Growth

Mankind Pharma is charting an aggressive strategy focused on financial discipline and market expansion, with plans to become debt-free by FY28 and almost debt-free by FY27, down from a current net debt of ₹5,200 crore. Managing Director Rajeev Juneja emphasized a conservative approach to debt management, signaling strong fiscal prudence. The company is also positioning itself at the forefront of India’s emerging obesity treatment market, aiming to be among the first to launch GLP-1 (Glucagon-Like Peptide-1) therapies, a fast-growing segment expected to surge over the next decade. In parallel, Mankind is scaling its consumer health business, which contributes 8–9% of revenue, through a dedicated OTC division. The company expects this segment to grow in the high teens, driven by strong performance from brands like Gas-o-Fast. It recently expanded its portfolio by acquiring and launching Nemulid from Panacea Biotech. Exports account for 13–14% of revenues, with potential for double-digit growth ahead, despite minimal current contribution from the US (1%). With strategic moves in debt reduction, innovation, acquisitions, and global expansion, Mankind Pharma is building momentum to strengthen its leadership in both prescription and consumer healthcare spaces, while aligning with rising demand for preventive and chronic disease treatments.